Neuronavigated aiTBS for TRD

Starting soon · Not applicable · Has a placebo group

Conditions studied: Treatment Resistant Depression (TRD)

In brief

The purpose of this study is to confirm the efficacy of two recently introduced repetitive transcranial magnetic stimulation (rTMS) interventions - accelerated intermittent theta-burst stimulation (aiTBS) and individualized neuronavigation - in treatment-resistant depression (TRD). Using a three-arm design (neuronavigated aiTBS, non-neuronavigated aiTBS, and sham), this randomized controlled trial (RCT) is the first to specifically investigate the incremental benefit of neuronavigation within an accelerated stimulation protocol, as well as the first confirmatory RCT comparing the efficacy of each of these active treatments vs. sham, overcoming previous generalizability issues and being conducted in an independent, multicenter US TRD sample.

Key facts

Study ID

NCT07329153

Run by

University of Texas Southwestern Medical Center

People needed

247

Starts

2026-07-01

Expected to finish

2031-09-01

Last updated by the study team

2026-01-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age: 18 to 65 years at the time of consent
• Diagnosis: Current major depressive episode (MDE) in the context of unipolar major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by clinical psychiatric interview
• Treatment Resistance: Documented failure to respond to at least two adequate antidepressant trials on the Antidepressant Treatment History Form-Short Form (ATHF-SF). An adequate trial is defined as:
• Antidepressant medication at the maximum tolerated dose for at least 6 weeks, OR
• Evidence-based psychotherapy consisting of at least 12 sessions
• Depression Severity: Montgomery-Åsberg Depression Rating Scale (MADRS) score >19 at screening, indicating moderate to severe depression
• Medication Stability: No changes in antidepressant medication type or dose for at least 6 weeks prior to randomization. Stable doses of permitted medications must be maintained throughout the trial
• Informed Consent: Demonstrated capacity to provide written informed consent and comply with study procedures
• Availability: Ability to attend treatment sessions for 15 consecutive workdays (approximately 90 minutes per day) and complete assessments including 4-hour evaluations at baseline and endpoint

You may not qualify if…

• Psychiatric Exclusions:
• Any psychiatric disorder other than MDD and comorbid anxiety disorders, including but not limited to:
• (i) Bipolar disorder (Type I or II) (ii) Schizophrenia spectrum or other psychotic disorders (iii) Post-traumatic stress disorder (PTSD) (iv) Attention-deficit/hyperactivity disorder (ADHD) (v) Autism spectrum disorder (ASD) (vi) Obsessive-compulsive disorder (OCD) (vii) Current DSM-5 substance-use disorder (abuse or dependence) within the past 6 months, except nicotine dependence
• Personality disorder confirmed on clinical interview by an experienced study psychiatrist
• Severe suicidal ideation with structured plan (HDRS-17 item 3 score >2) or as determined by the evaluating psychiatrist
• Depressive symptoms better explained by another psychiatric condition, a medical condition, substance use, or use of medications
• Medical and Neurological Exclusions:
• Any neurological disorder including but not limited to:
• (i) History of seizure disorder or epilepsy (ii) Family history of epilepsy (first-degree relatives) (iii) Significant head trauma with loss of consciousness >5 minutes (iv) Stroke or transient ischemic attack (v) Neurodegenerative disorders (e.g., Parkinson's disease, multiple sclerosis, dementia) (vi) Brain tumor or intracranial mass lesion
• Unstable medical condition, defined as any condition requiring acute medical intervention or hospitalization within the past 3 months, or any condition that in the investigator's judgment could affect participant safety or study outcomes
• Contraindications to TMS/MRI:
• Presence of ferromagnetic material in or near the head, including:
• (i) Intracranial implants (e.g., aneurysm clips, shunts, stimulators) (ii) Cochlear implants or hearing aids (iii) Metallic facial tattoos or permanent makeup (iv) Other implanted medical devices deemed unsafe for MRI/TMS
• Inability to tolerate MRI scanning due to claustrophobia or other reasons
• Medication Exclusions:
• Current use of medications known to significantly alter cortical excitability:
• Anticonvulsants (including those used for mood stabilization)
• Psychostimulants
• Lithium
• Benzodiazepines exceeding 10mg diazepam-equivalent daily dose
• Prior Treatment Exclusions:
• Electroconvulsive therapy (ECT) (≥ 6 sessions) in the current depressive episode
• Ketamine or esketamine treatment (≥ 6 sessions) in the current depressive episode
• Use of rTMS/iTBS (≥ 15 sessions) during the current depressive episode
• Vagus nerve stimulation (VNS) or deep brain stimulation (DBS) implantation

Where it is running

• University of California at San Diego (UCSD) — San Diego, California, United States
• Cornell University — New York, New York, United States
• University of Texas Southwestern Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.